An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons

Journal of Infectious Diseases

Volumn 185, Issue 3, 2002, Pages 306-314

  Saavedra Lozano, Jesús ^a,b   McCoig, Cynthia ^a,b   Xu, Jinbo ^a   Cao, Yanying ^a   Keiser, Philip ^d   Ghetie, Victor ^a,c   Siliciano, Robert F ^e   Siliciano, Janet D ^e   Picker, Louis J ^a,f   Ramilo, Octavio ^a,b,c   Vitetta, Ellen S ^a,c  

^a Cancer Immunobiology Center   (United States)

^b Departments of Pediatrics   (United States)

^c Departments of Microbiology   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD25 ANTIBODY IMMUNOTOXIN; IMMUNOTOXIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL DIVISION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MEMORY CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; IMMUNOTOXINS; RECEPTORS, INTERLEUKIN-2; VIREMIA; VIRUS LATENCY;

EID: 0036467792     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338565     Document Type: Article

References (61)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
3. + T cells provides a mechanism for lifelong persistence of HIV- 1, even in patients on effective combination therapy
4. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
5. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
6. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
7. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
8. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
9. Latency and reservoirs for HIV-1
10. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen
11. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
12. Generation of HIV latency during thymopoiesis
13. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency
14. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection
15. + T cells in acute human immunodeficiency virus type 1 infection
16. Ongoing HIV dissemination during HAART
17. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
18. Decay characteristics of HIV-1-infected compartments during combination therapy
19. Interleukin 2 treatment for HIV infection
20. + T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy
21. Randomized controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
22. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
23. HIV-1 and HAART: A time to cure, a time to kill
24. - quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus
25. New uses for old drugs in HIV infection: The role of hydroxyurea, cyclosporin and thalidomide
26. Activity of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection
27. Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus
28. Antiretroviral therapy plus cyclophosphamide to diminish HIV DNA in lymphoid tissue
29. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
30. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response
31. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
32. - T cells in acute HIV infection in vitro
33. Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection
34. An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro
35. - resting T cells cannot be infected de novo with HIV-1
36. Fitting limiting dilution experiments with generalized linear models in a test of the single-hit poisson assumption
37. Clonal analysis of B cells induced to secrete IgG by T cell-derived lymphokine(s)
38. Design and analysis of serial limiting dilution assays with small sample sizes
39. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond
40. Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1
41. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumors in mice
42. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
43. Immune reconstitution with donor-derived memory/effector T cells after orthotopic liver transplantation
44. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus
45. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
46. Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals
47. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro
48. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
49. Immune control of HIV-1 after early treatment of acute infection
50. Clinical studies with deglycosylated ricin A-chain immunotoxins
51. + T cells comprise both naive and memory cells
52. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
53. + subsets defined by CD57, CD27, and CD45 isoforms
54. - T cells
55. CD8 naive T cell counts decrease progressively in HIV-infected adults
56. Altered representation of naive and memory CD8 T cell subsets in HIV-infected children
57. + T cells contain cells with high levels of lymphocyte function-associated antigen-1 expression, a phenotype of primed T cells
58. + T cell homeostasis and function in advanced HIV disease
59. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
60. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection
61. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy